Aortic Aneurysm Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Aortic aneurysm surgery encompasses the surgical and endovascular procedures used to prevent rupture of pathologically dilated segments of the aorta — the body's main arterial trunk running from the heart through the chest and abdomen. The aorta is considered aneurysmal when its diameter exceeds 1.5 times the expected normal diameter; in practical terms, an abdominal aortic aneurysm (AAA) is diagnosed when the infrarenal aortic diameter exceeds 3.0 cm, and intervention is typically recommended when it reaches 5.5 cm in men or 5.0 cm in women due to the substantially increased rupture risk above these thresholds.

The two principal surgical approaches are open aortic repair and endovascular aortic repair (EVAR for infrarenal AAA; TEVAR for thoracic aneurysms). Open repair involves a laparotomy or retroperitoneal incision, cross-clamping the aorta, excising or opening the aneurysm sac, and replacing the diseased aortic segment with a synthetic Dacron or PTFE graft. EVAR deploys a stent-graft device through small femoral artery incisions, lining the aorta from the inside under fluoroscopic guidance and excluding the aneurysm sac from arterial pressure without open surgery.

The management of aortic aneurysms involves a careful balance: the perioperative mortality of elective repair (0.5–1.6% for EVAR; 3–5% for open repair in fit patients) must be weighed against the natural history risk of rupture without treatment (approximately 25% annual risk for a 7 cm AAA; over 30% for ruptured AAA mortality). Emergency repair of ruptured AAA carries overall mortality of 80–85% (including pre-hospital deaths), reinforcing the critical importance of identifying and electively repairing aneurysms before rupture.

Infrarenal abdominal aortic aneurysm (AAA) — involving the segment of the aorta below the renal arteries — is the most common aortic aneurysm, occurring in 4–8% of men over 65 and 0.5–1.5% of women. It is strongly associated with atherosclerosis, smoking, hypertension, and male sex. AAA screening with abdominal ultrasound in 65-year-old men is recommended by NICE and the USPSTF; detected aneurysms are monitored by serial ultrasound and repaired when they reach the size threshold.

Thoracic aortic aneurysm (TAA) — involving the ascending aorta, aortic arch, or descending thoracic aorta — is repaired by open surgery via sternotomy (for ascending and arch aneurysms) or thoracotomy, or by TEVAR (for descending thoracic aneurysms with suitable anatomy). Connective tissue disorders (Marfan syndrome — FBN1 mutation; Loeys-Dietz syndrome; Ehlers-Danlos syndrome Type IV) cause aggressive thoracic aortic disease at younger ages and require earlier intervention at smaller diameters. Thoracoabdominal aortic aneurysms (TAAA) involving both thoracic and abdominal segments are among the most challenging vascular operations, carrying higher mortality and paraplegia risks.

Patients with AAA meeting size criteria (greater than 5.5 cm in men, greater than 5.0 cm in women) or with aneurysms growing faster than 1 cm/year, or symptomatic aneurysms (back or abdominal pain attributable to the aneurysm), are candidates for elective repair. Fitness for repair is assessed with cardiopulmonary exercise testing (CPET), echocardiography, pulmonary function tests, and renal function. Patients unfit for open repair (severe cardiac or respiratory disease) may be offered EVAR if anatomy is suitable.

EVAR anatomical suitability requires: an adequate infrarenal neck length (greater than 10 mm), neck angulation below 60°, adequate iliac artery access (diameter greater than 7 mm and without excessive tortuosity), and absence of very large aneurysm diameter (which limits available device options). Approximately 60% of AAAs are anatomically suitable for standard EVAR. Complex EVAR techniques (fenestrated EVAR — FEVAR; branched EVAR) extend endovascular repair to juxtarenal and suprarenal aneurysms with involvement of visceral artery origins. Contraindications to repair include very short life expectancy from other causes (less than 2 years), patient refusal after informed consent, and anaesthetic risk deemed prohibitive even for EVAR.

EVAR is performed under general anaesthesia (or epidural/local for selected high-risk patients) in a hybrid operating theatre equipped with fluoroscopy. Through bilateral femoral artery exposure or percutaneous puncture, a bifurcated stent-graft device (Medtronic Endurant, Cook Zenith, Gore Excluder, Endologix AFX — depending on anatomical requirements) is delivered via large-bore sheath systems and deployed under real-time fluoroscopic guidance. The procedure takes 1.5–3 hours. Completion angiography confirms device position and the absence of endoleak (contrast opacification of the excluded aneurysm sac). Most EVAR patients are mobilised the same day or next morning.

Open AAA repair is performed via midline laparotomy or left retroperitoneal approach. The aorta is clamped above and below the aneurysm, the sac opened, and a Dacron tube or bifurcated graft sutured in place before the aortic clamp is removed. The sac is then closed around the prosthesis to prevent graft-enteric fistula. Open repair provides definitive, durable repair without the need for life-long surveillance for device complications and is preferred in younger fit patients (under 65). For thoracic aneurysms, TEVAR uses a single-body stent-graft deployed via the femoral artery to exclude descending thoracic aneurysms, with spinal drain placement to reduce paraplegia risk from spinal artery compromise.

Selecting the most appropriate Aortic Aneurysm Surgery approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Elective EVAR in the landmark EVAR-1 trial demonstrated 30-day mortality of 1.7% compared to 4.7% for open repair — a 64% relative reduction in procedural mortality. EVAR patients also had shorter hospital stays (mean 3 days vs 8 days), lower blood loss, and faster functional recovery. However, at 5 years, overall survival between the two groups was similar, with EVAR having higher rates of secondary interventions (for endoleak and device failure) and greater requirement for ongoing surveillance.

Open repair provides more durable long-term results: once healed, an open repair requires minimal ongoing surveillance and secondary intervention rates are less than 5% at 10 years compared to 15–20% for EVAR. For patients with long life expectancy (over 20 years), the durability of open repair may outweigh the short-term mortality advantage of EVAR. For emergently ruptured AAA, EVAR (when the patient reaches hospital alive and anatomy allows) has lower 30-day mortality than open repair (25–40% vs 30–50%) based on pooled data, though results vary significantly by centre and patient selection.

Open AAA repair risks include cardiac events (myocardial infarction in 5–10%), respiratory complications (atelectasis, pneumonia in 10–20%), acute kidney injury (10–15%), bowel ischaemia from inferior mesenteric artery compromise (1–2%), and spinal cord ischaemia (paraplegia) — primarily relevant for suprarenal and thoracoabdominal repairs (up to 5% in TAAA). Sexual dysfunction from hypogastric plexus injury affects 25–40% of male patients following open infrarenal AAA repair.

EVAR-specific complications include endoleak (type I — inadequate proximal or distal seal; type II — retrograde sac filling from branch vessels; type III — junctional failure) occurring in 10–20% of patients on long-term surveillance, requiring re-intervention in approximately 5% per year. Device migration, limb occlusion (5%), and conversion to open repair (3%) are additional concerns. Life-long CT surveillance (or validated duplex ultrasound) is mandatory after EVAR to detect these complications early. Late open conversion for EVAR failure carries higher mortality than primary open repair.

EVAR patients are discharged at 2–3 days, can mobilise fully within 1 week, and typically return to normal activities within 4 weeks. CT angiography is performed at 1 month, 6 months, and annually thereafter for EVAR patients. Patients with Type II endoleak on surveillance require annual CT to monitor aneurysm sac diameter — growth of more than 5 mm warrants re-intervention. Patients with a stable aneurysm sac diameter and no endoleak can be safely monitored by duplex ultrasound at annual intervals.

Open repair patients are hospitalised 7–10 days and require 6–8 weeks' recovery at home. Heavy lifting and driving are restricted for 6 weeks. Follow-up is less intensive than EVAR: graft surveillance with CT or ultrasound is recommended at 5 years and then symptom-guided. All aortic aneurysm patients require long-term cardiovascular risk optimisation: statin therapy, antiplatelet therapy (aspirin), blood pressure control (target below 130/80 mmHg), and smoking cessation are associated with improved long-term survival and slowed progression of residual aortic disease.

Aortic aneurysm surgery is among the more expensive vascular procedures. EVAR in the United States costs $50,000–100,000 for the device and hospital stay, with the stent-graft device itself costing $10,000–30,000. Open AAA repair costs $30,000–70,000 but does not carry device costs. Emergency ruptured AAA repair including ICU stay can cost $100,000–200,000. Insurance typically covers these procedures for medically appropriate indications.

For patients considering planned surgery abroad, major vascular surgery centres in India (Apollo, Fortis, Manipal) perform EVAR for $8,000–18,000 and open AAA repair for $6,000–14,000 — savings of 75–85% versus US prices. Indian vascular surgeons have trained at major US and European vascular centres and use the same imported stent-graft systems. Thailand offers EVAR at $12,000–25,000 and open repair at $10,000–20,000. Pre-operative CT angiography sent digitally enables case planning before patient travel. Most centres recommend a 5–7 day hospital stay post-EVAR.

For small aneurysms (AAA below 5.5 cm) not meeting intervention threshold, the appropriate management is surveillance ultrasound (at 3-year intervals for 3.0–4.4 cm; annually for 4.5–5.4 cm) combined with aggressive cardiovascular risk factor optimisation. Statin therapy (targeting LDL below 1.8 mmol/L) slows AAA growth by approximately 1–2 mm/year based on meta-analyses. Smoking cessation is the single most effective intervention to slow aneurysm growth. Beta-blockade with atenolol or losartan (the latter particularly in Marfan syndrome) reduce aortic wall stress.

There are currently no validated pharmacological therapies proven to prevent aneurysm rupture in patients meeting size criteria for repair — these patients require surgery. Novel endovascular approaches including in-situ laser fenestration and parallel graft techniques (chimney/periscope EVAR) extend endovascular treatment to complex juxta- and pararenal aneurysms, potentially avoiding the morbidity of open repair in high-risk patients who previously had no endovascular option.